Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Vomiting 12Nausea 12Neoplasms 8Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Lung Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Radiation Injuries 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × Olanzapine × Clear all
NCT07442890 2026-03-02

A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron

Henan Cancer Hospital

Phase NA Not yet recruiting
238 enrolled
Thoracic

Lung Neoplasms

NCT03571126 2021-07-13

Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer

Zunyi Medical College

Phase 4 Unknown
156 enrolled
Thoracic

Lung Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡